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Oncolytic viruses (OVs) selectively infect, replicate in, and kill
tumor cells. For a long time, the therapeutic efficacy of OVs was
thought to depend mainly on this mechanism of direct viral oncol-
ysis. Nowadays, however, the post-oncolytic anti-tumor activity
induced by the OV therapy is considered a key factor for an efficient
therapeutic activity. The research topic addresses these issues and
discusses future strategies how to further optimize OVs anti-tumor
activity.
The first two articles deal with viral oncolysis and the immune
response. Guo et al. (1) from the University of Pittsburgh Cancer
Institute (USA) point out that dying the right way is a key to elic-
iting potent anti-tumor immunity. They describe that OVs induce
mostly immunogenic cancer cell death (ICD) including immuno-
genic apoptosis, necrosis/necroptosis, pyroptosis, and autophagic
cell death. A review of recent advances in our understanding of
danger signals is followed by a discussion of potential combina-
tion strategies to target cells into specific modes of ICD. Thorne (2)
from the same Institution argues in his perspective article that the
immune response raised by an OV can also hinder optimal ther-
apeutic activity and repeat dosing. Using oncolytic vaccinia virus
(VV) as an example, Thorne summarizes approaches to enhance
the anti-tumor immune response by the introduction of immune
stimulatory transgenes. His article points our attention also toward
interesting new alternative strategies.
The next four articles review and discuss in more detail post-
oncolytic anti-tumor immune responses. Gujar and Lee (3) from
the Dalhousie University of Halifax (Canada) discuss how OV-
induced immunological events override tumor-associated antigen
(TAA) presentation impairment and promote appropriate T cell
interaction with antigen-presenting cells (APC). Woller et al. (4)
from the Medical School in Hannover (Germany) review the
role of viral oncolysis for induction of ICD including autophagy,
DAMPs and PAMPs, and the ER–stress response. Finally, they
highlight developments for exploiting the vaccinative potential
of oncolytic virotherapy. Moehler et al. (5) from the University
Medical Center in Mainz (Germany) together with Jean Romme-
laere from the DKFZ, Heidelberg (Germany) draw our attention
to oncolytic parvoviruses and review their evidence that these
can trigger maturation of dendritic cells (DCs) and induce acti-
vation of antigen-specific cytotoxic T cells. Finally, they discuss
the clinical potential of the immunovirotherapy concept and
its combination with new targeted therapies or with immune
checkpoint blocking antibodies. Janelle and Lamarre (6) from
the INRS-Institut Armand-Frappier in Quebec (Canada) dis-
cuss the question of how to assess anti-tumor immunity. They
exemplify this by reviewing experimental studies with B16 mouse
melanoma, which is treated by vesicular stomatitis virus (VSV)
variants.
How can OVs be harnessed or combined with other agents such
as antibodies to mediate stronger anti-tumor effects? This question
is discussed by the following two manuscripts. Bauzon and Her-
miston (7) from the Bayer HealthCare US Innovation Center in
San Francisco (USA) propose to merge OVs with immune check-
point blocking antibodies. Immune checkpoints refer to a number
of inhibitory pathways that play crucial roles in maintaining self-
tolerance and immune homeostasis. The discovery and targeting
of immune checkpoints has opened a new immunotherapeutic
avenue generating very promising clinical results. Arguments are
put forward to combine this strategy with an OV therapy to create
synergies between both approaches. This might result in enhanced
safety and efficacy and would be also economically advantageous.
Schirrmacher and Fournier (8) from the DKFZ, Heidelberg (Ger-
many) and from the IOZK in Cologne (Germany) put forward
in a perspective article a new concept of a multimodal cancer
therapy involving oncolytic Newcastle disease virus (NDV), autol-
ogous immune cells (activated T cells and/or polarized DC1), and
bi-specific antibodies (bsAbs). The bsAbs they created are NDV-
specific single-chain (scFv) antibodies fused with anti-CD3 or
anti-CD28 T cell activating scFvs. These reagents, upon attach-
ment to NDV infected tumor cells, are reported to have a strong
potential to activate cancer patients T cells, including TAA-specific
memory T cells and not TAA-specific naïve T cells. Such ex vivo
activated autologous T cells can be transferred back to the patient.
To increase their tumor targeting efficacy, it is suggested to pre-
activate the tumor microenvironment by low dose irradiation
or by local hyperthermia. Tumor targeting of grafted T cells is
suggested to become also improved via cell-bound tri-specific
antibodies targeting a tumor introduced viral antigen such as
HN of NDV.
Delivery of OVs is another important aspect for achievement
of optimal effects. Tai and Auer (9) from the Ottawa Hospi-
tal Research Institute, Ottawa (Canada) argue that the optimal
time point should be either pre- or post-operative to counteract
surgery induced immunosuppression and to attack post-operative
metastases. They review their preclinical surgery models, in which
pre-operative OVs prevented post-operative NK cell dysfunction
and attenuated tumor dissemination. Altomonte and Ebert (10)
from the Klinikum rechts der Isar, Munich (Germany) discuss
the particular challenges of OV therapy for hepatocellular car-
cinoma as well as some potential strategies for modulating the
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immune system and synergizing it with the hepatic microenviron-
ment. Combination strategies involving the adoptive transfer of
immune cells together with OVs are expected as an exciting new
approach.
Successful therapy using OVs will ultimately depend on effec-
tively navigating the delicate balance between the anti-viral
response and the anti-tumor immune response such as to min-
imize the former in the short term and maximize the latter in the
long term. As outlined by Forbes et al. (11) from the Ottawa Hos-
pital Research Institute, Ottawa (Canada), several approved drugs
and novel small molecules can be effective tools to dampen the
innate and adaptive anti-viral responses, increase the anti-tumor
immune response, or both. Such approaches are discussed to be
undoubtedly context dependent (e.g., tumor type and tumor site)
and OV-dependent. This topic of combining oncolytic virother-
apy with chemotherapy is further discussed by Nguyen et al.
(12) from the McMaster University, Hamilton (Canada). With
a particular focus on pharmaceutical immunomodulators they
discuss how specific therapeutic contexts may alter the effects of
these synergistic combinations and their implications for future
clinical use.
It is remarkable to what extent experts from Canada, Germany,
and the USA are in accord in this e-book by emphasizing the poten-
tial importance of OVs on systemic T cell-mediated anti-tumor
immunity.
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